At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NUVB Nuvation Bio, Inc.
Trading 09-17 14:03:10 EDT
6.16
+0.38
+6.49%
High6.16Low5.92Vol3.26M
Open5.96D1 Closing5.78Amplitude4.15%
Mkt Cap2.16BTradable Cap1.62BTotal Shares351.12M
T/O19.78MT/O Rate1.24%Tradable Shares264.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nuvation Bio announces FDA approval of sNDA for Ibtrozi
TIPRANKS  ·  09-17 19:35
Nuvation Bio announces FDA approval of sNDA for Ibtrozi
Nuvation Bio Wins FDA Nod to Update Ibtrozi Label with 49.7-Month Response Duration in TRUST-I Study
Reuters  ·  09-17 19:31
Nuvation Bio Wins FDA Nod to Update Ibtrozi Label with 49.7-Month Response Duration in TRUST-I Study
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi® (Taletrectinib) with Updated Duration of Response in Tki-NaÏVe Advanced Ros1-Positive Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  09-17 19:30
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi® (Taletrectinib) with Updated Duration of Response in Tki-NaÏVe Advanced Ros1-Positive Non-Small Cell Lung Cancer
Nuvation Bio - no Changes to Ibtrozi Safety Labeling; no New Safety Signals Identified
THOMSON REUTERS  ·  09-17 19:30
Nuvation Bio - no Changes to Ibtrozi Safety Labeling; no New Safety Signals Identified
Nuvation Bio Price Target Maintained with a $11.00/Share by Wedbush
Dow Jones  ·  09-16 20:34
Nuvation Bio Price Target Maintained with a $11.00/Share by Wedbush
Nuvation Bio CEO, CFO to Present at Citi Biopharma Conference Fireside Chat
Reuters  ·  09-03
Nuvation Bio CEO, CFO to Present at Citi Biopharma Conference Fireside Chat
Nuvation Bio CSO Gary Hattersley Disposes of Class a Common Shares Worth $709,240
Reuters  ·  08-22
Nuvation Bio CSO Gary Hattersley Disposes of Class a Common Shares Worth $709,240
Cantor Fitzgerald Initiates Nuvation Bio at Overweight
MT Newswires Live  ·  08-21
Cantor Fitzgerald Initiates Nuvation Bio at Overweight
Nuvation Bio Initiated at Overweight by Cantor Fitzgerald
Dow Jones  ·  08-21
Nuvation Bio Initiated at Overweight by Cantor Fitzgerald
Nuvation Bio initiated with an Overweight at Cantor Fitzgerald
TIPRANKS  ·  08-21
Nuvation Bio initiated with an Overweight at Cantor Fitzgerald
Nuvation Bio Wins FDA Fast-Track Status for Safusidenib in IDH1-Mutant Glioma
Reuters  ·  08-20
Nuvation Bio Wins FDA Fast-Track Status for Safusidenib in IDH1-Mutant Glioma
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of Idh1-Mutant Glioma
THOMSON REUTERS  ·  08-20
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of Idh1-Mutant Glioma
Nuvation Bio Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $13
THOMSON REUTERS  ·  08-18
Nuvation Bio Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $13
Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership
Simply Wall St.  ·  08-11
Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership
RBC Adjusts PT on Nuvation Bio to $20 From $19, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-07
RBC Adjusts PT on Nuvation Bio to $20 From $19, Maintains Outperform Speculative Risk Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)
TIPRANKS  ·  08-07
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)
Nuvation Bio Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06
Nuvation Bio Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Nuvation Bio Posts Corporate Presentation Highlighting Ibtrozi ROS1 Lung Cancer Franchise
Reuters  ·  08-06
Nuvation Bio Posts Corporate Presentation Highlighting Ibtrozi ROS1 Lung Cancer Franchise
Earnings Flash (NUVB) Nuvation Bio Posts Q2 Net Loss of $0.18 per Share, vs. FactSet Est of $0.15 Loss
MT Newswires Live  ·  08-06
Earnings Flash (NUVB) Nuvation Bio Posts Q2 Net Loss of $0.18 per Share, vs. FactSet Est of $0.15 Loss
Nuvation Bio Q2 Revenue Beats Estimates on Ibtrozi Growth
Reuters  ·  08-06
Nuvation Bio Q2 Revenue Beats Estimates on Ibtrozi Growth

Introduction

Company Name.
Nuvation Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .
Issue price:
--